- Hindi news
- Db original
- DB Explainer | Bhaskar Explainer | DB Coronavirus Vaccine Tracker | Russia Shares Vaccine Data With India Likely To Roll Out For Civilian Use This Week | Covid 19 Vaccine Update News | Covid 19 Vaccine Latest News
- India overtakes Brazil in the second most number case
- If the series continues, it will leave America behind in 12-15 days.
India has overtaken Brazil among the Corona Infections. After India, the highest number of cases is in India. If this trend continues, India will soon become the country with the most Kovid-19 cases in the world. In such a situation, the government has also stepped up efforts to control the situation.
Russia and China have allowed their own vaccines to be used even before the results of Phase-3 trials. In view of this, the Government of India is also eyeing the Russian vaccine. Data related to vaccine trials were sought from Russia. Like the Oxford / AstraZeneca vaccine, Gamalaya's vaccine may have trials in India. This will increase the chances of getting the vaccine at the earliest.
India had asked for data from Russia
- The corona vaccine SPUTNIK V of the Gamalaya Research Institute of Epidemiology and Microbiology of Moscow was under suspicion. The reason was lack of data. The medical journal Lancet has published the results of its trials.
- According to a study published in Lancet, SPUTNIK V is effective as well as safe. The Russian Research Institute has shared the data of vaccine trials with Indian authorities after publishing in Lancet. According to a study published in Lancet, vaccine trials were conducted on 76 people and this has triggered immune response in them.
- Indian Ambassador to Russia DB Venkatesan Verma as well as Secretary of the Department of Biotechnology, Renu Swaroop has coordinated this entire data transfer. Experts are evaluating the comprehensive data from Gamalaya in India. Phase-3 trials can also take place in India by taking necessary permissions from regulators.
- According to the official website of SPUTNIK V, Russia plans to phase-3 trials of this vaccine in Saudi Arabia, UAE, Brazil and the Philippines. It is also written that 20 countries including India have shown interest in the vaccine.
From this week, the public will start getting vaccines in Russia
- Russian Medical Watch Dog will check the vaccine quality this week and approval can be given before 13 September. After this, the government will authorize this vaccine for civilian use.
- Associate member of the Russian Academy of Sciences Denis Logunov said that while most of the country is still at different stages of vaccine testing, Russia will approve SPUTNIK V vaccine for civilian use this week. The first batch will also be released this week.
Initial data for vaccine will be available by 15 September
- More than 175 vaccines are being produced worldwide. There are also about 35 vaccines that are in the phase of clinical trials. That is, their phase 1, phase 2 or phase 3 trials are going on.
- Eight vaccine candidates are in phase-3 trials. Coveshield is at the forefront of Oxford / AstraZeneca. Its trials have been started in India, Brazil and South Africa.
- The UK drugmaker has signed a deal with the Serum Institute of India (SII) in Pune to produce one billion doses.
- SII started Phase-2 and Phase-3 trials last week. There will be 1,600 volunteer enrols. AstraZeneca has also started trials in the US. There will be 30,000 volunteers involved. Trials will also start in Russia and Japan soon.
Sinovec vaccinated employees and their families
- China has allowed emergency use of Synovac as well as the vaccines of government firms Sinopharm and Cancino Biologics. However, the results of phase-3 trials of all three vaccines have not yet been reported.
- Meanwhile, reports are being quoted from the CEO of Sinovec that 90 percent of the company's staff and their families have been vaccinated. Although it is claimed that the vaccine has been applied on a voluntary basis, the numbers have not been revealed.
- The Synovac vaccine is being called CoronVac, and has been approved for emergency use only in July. Phase-3 trials have started in Brazil and Indonesia. There are 34 vaccine clinical trials in the phase, 8 of them are sugar.